BELLUS Health Inc.
BELLUS Health Inc. (BLU) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
blu · stock forecast · 6 analysts (3M) · FMP · updated Apr 26, 2024
Analyst Rating & Consensus
Based on 6 Wall Street analysts in the past 3 months
Hold
6 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$14.75
Consensus
$14.75
+0.1% upside
Low
$14.75
Median: $14.75 · Last Close: $14.74
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $14.77 | ↑ 0.20% |
1-day model range: $14.76–$14.78. Peak: $14.78 (+0.20%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · BLU · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-05-15 | RBC Capital | Maintains | Sector Perform→Perform |
| 2023-05-14 | RBC Capital | Maintains | Sector Perform→Perform |
| 2023-04-19 | RBC Capital | Downgrade ↓ | Outperform→Perform |
| 2023-04-19 | Jefferies | Downgrade ↓ | Buy→Hold |
| 2023-04-18 | Jefferies | Downgrade ↓ | Buy→Hold |
| 2023-04-18 | RBC Capital | Downgrade ↓ | Outperform→Perform |
| 2023-04-18 | Evercore ISI Group | Downgrade ↓ | Outperform→In Line |
| 2023-04-17 | Evercore ISI Group | Downgrade ↓ | Outperform→In Line |
| 2022-09-30 | RBC Capital | Maintains | Outperform→Outperform |
| 2022-09-29 | RBC Capital | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on BELLUS Health Inc. (BLU) stock. Of the recent 32 rating actions, 0 were upgrades and 8 were downgrades. 6 analysts currently cover BLU.
Analyst Recommendation Trends
BLU analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
—
Revenue Next Year
—
EPS This Year
—
EPS Next Year
—
EPS ForecastReported vs Estimated
Analysts forecast BLU EPS of $— for the current fiscal year, based on estimates from 0 analysts. The BLU revenue forecast is — for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The BLU stock forecast is supported by two independent data sources: analyst consensus ratings from 6 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus BLU price target is $14.75 (+0.1% upside), with an analyst consensus of Hold.
The BLU short-term stock prediction for tomorrow is $14.77 (+0.20%).
BELLUS Health Inc. trades on NASDAQ under the ticker BLU. The BLU stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 33% of covering analysts.
Frequently asked questions
BLU forecast · 8 questionsAccording to 6 Wall Street analysts, the average 12-month BLU price target is $14.75, with a high forecast of $14.75 and a low of $14.75. The median price target is shown in the chart above when available. This implies +0.1% potential upside from the current price of $14.74.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.